Skip to main content
Kids’Zone at MSF Thalassemia programme

Treating Syrian children suffering from thalassemia

War in Gaza:: find out how we're responding
Learn more

Médecins Sans Frontières (MSF) teams in Lebanon are treating Syrian refugee children for thalassemia. A genetic blood disorder, in its acute forms thalassemia requires demanding treatment that we provide in a paediatric hospital in the city of Zahle in Bekaa Valley, eastern Lebanon.


Syrian kids with thalassemia in Lebanon

What is thalassemia?

Thalassemia is a disease caused by an alteration in the genes required to synthesise haemoglobin, which transports oxygen throughout the body. The greater the number of altered genes, the more severe the disease. The life expectancy of untreated patients can be considerably shortened. In severe cases, regular blood transfusions are needed to compensate for the lack of haemoglobin.

“There’s a complication with frequent transfusions”, says Dr Amber Alayyan, medical manager of MSF programmes in Lebanon. “These can cause iron overload, which can result in heart or liver disease. This is why thalassemia patients need iron chelators [drugs] to lower iron levels in the body.”

MSF providing comprehensive care for hereditary disease

MSF provides comprehensive care in the paediatric department in Elias Haraoui hospital in Zahle. The team start by diagnosing the disease. Parents are often aware their children have the disease because it’s a hereditary disorder and other relatives are affected, so it just takes a blood test to confirm the diagnosis.

In other cases, when a child is pale, weak and shows signs of anaemia, blood tests are carried out to establish the cause, and haemoglobin electrophoresis then confirms whether or not it is thalassemia.

Kids’Zone at MSF Thalassemia programme
An MSF nurse conducts a blood test while 2-year-old Fatmeh waits for her blood transfusion for her thalassemia. Zahle, Lebanon, May 2019.
Joffrey Monnier/MSF

The Syrian children treated at Elias Haraoui hospital are given blood transfusions and the appropriate medication is prescribed as a first-line drug. The MSF team takes blood samples to monitor the children’s treatment and also keeps a watchful eye on their general state of health.

If any other health issues are identified, they are referred to the appropriate specialist. They also tell parents about the treatment that’s been prescribed and, very importantly, that once the disease is being treated their children can lead normal lives.

“It’s really important for the team to have a relationship with the families”, says Fouzia Bara, MSF head of mission in Lebanon. “Some parents are distressed because they think their child won’t be able to get married and will have no future. We reassure them and tell them that their child can live with the illness, which gives them hope.”

Providing care to Syrian refugees in Lebanon

MSF is currently treating 64 patients in the hospital in Zahle, all of them Syrian children. They have access neither to the state-provided care programme, which is exclusively for Lebanese nationals, nor to coverage by the United Nations Refugee Agency (UNHCR).

We plan to scale-up our activities and treat 100 Syrian children by the end of the year. Teams can’t take on any more than 100 patients due to the extremely high cost of the drugs. However, with over one million Syrians now living in Lebanon, there are likely many more refugee children afflicted with thalassemia, because it is particularly prevalent in their home country. To treat more people though  would require being able to have access to a cheaper drug.

Thalassemia affects countries in the Middle East, such as Lebanon and Syria, and in the Mediterranean basin; the word thalassemia derives from the Greek thalassa that means sea. But, a relatively unknown disease, it is also prevalent in other countries like Pakistan and Afghanistan where access to treatment is impacted still further by instability and violence.

Up Next
Voices from the Field 3 May 2019